The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells

Journal of Immunology

Volumn 187, Issue 5, 2011, Pages 2252-2260

  El Haddad, Najib ^a   Moore, Robert ^a   Heathcote, Dean ^b   Mounayar, Marwan ^a   Azzi, Jamil ^a   Mfarrej, Bechara ^a   Batal, Ibrahim ^a   Ting, Christopher ^a   Atkinson, Mark ^c   Sayegh, Mohamed H ^a   Ashton Rickardt, Philip G ^b   Abdi, Reza ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE MARKER; GRANZYME B; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 9; SERPINB9; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ARTICLE; BONE MARROW; CELL DEATH; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROTECTION; CELL RENEWAL; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESODERM; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELLS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SERPINS;

EID: 80052651871     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003981     Document Type: Article

References (58)

1. Tyndall, A., and F. A. Houssiau. 2010. Mesenchymal stem cells in the treatment of autoimmune diseases. Ann. Rheum. Dis. 69: 1413-1414.
2. Gonzalez-Rey, E., M. A. Gonzalez, N. Varela, F. O'Valle, P. Hernandez-Cortes, L. Rico, D. Buscher, and M. Delgado. 2010. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann. Rheum. Dis. 69: 241-248.
3. Parekkadan, B., A. W. Tilles, and M. L. Yarmush. 2008. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 26: 1913-1919.
4. Fiorina, P., M. Jurewicz, A. Augello, A. Vergani, S. Dada, S. La Rosa, M. Selig, J. Godwin, K. Law, C. Placidi, et al. 2009. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J. Immunol. 183: 993-1004.
5. El Haddad, N., D. Heathcote, R. Moore, S. Yang, J. Azzi, B. Mfarrej, M. Atkinson, M. H. Sayegh, J. S. Lee, P. G. Ashton-Rickardt, and R. Abdi. 2011. Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood 117: 1176-1183.
6. Spaggiari, G. M., A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta. 2006. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484-1490. (Pubitemid 43242385)
7. Prigione, I., F. Benvenuto, P. Bocca, L. Battistini, A. Uccelli, and V. Pistoia. 2009. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27: 693-702.
8. Erices, A., P. Conget, and J. J. Minguell. 2000. Mesenchymal progenitor cells in human umbilical cord blood. Br. J. Haematol. 109: 235-242. (Pubitemid 30340601)
9. Kassis, I., L. Zangi, R. Rivkin, L. Levdansky, S. Samuel, G. Marx, and R. Gorodetsky. 2006. Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplant. 37: 967-976. (Pubitemid 43792558)
10. Puissant, B., C. Barreau, P. Bourin, C. Clavel, J. Corre, C. Bousquet, C. Taureau, B. Cousin, M. Abbal, P. Laharrague, et al. 2005. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol. 129: 118-129. (Pubitemid 40524060)
11. Fernández, M., V. Simon, G. Herrera, C. Cao, H. Del Favero, and J. J. Minguell. 1997. Detection of stromal cells in peripheral blood progenitor cell collections from breast cancer patients. Bone Marrow Transplant. 20: 265-271. (Pubitemid 27389234)
12. Mansilla, E., G. H. Marín, H. Drago, F. Sturla, E. Salas, C. Gardiner, S. Bossi, R. Lamonega, A. Guzmán, A. Nuñez, et al. 2006. Bloodstream cells pheno-typically identical to human mesenchymal bone marrow stem cells circulate in large amounts under the influence of acute large skin damage: new evidence for their use in regenerative medicine. Transplant. Proc. 38: 967-969.
13. Ryan, J. M., F. P. Barry, J. M. Murphy, and B. P. Mahon. 2005. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond.) 2: 8.
14. François, M., R. Romieu-Mourez, S. Stock-Martineau, M. N. Boivin, J. L. Bramson, and J. Galipeau. 2009. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 114: 2632-2638.
15. Caligiuri, M. A. 2008. Human natural killer cells. Blood 112: 461-469.
16. Biron, C. A. 2010. More things in heaven and earth: defining innate and adaptive immunity. Nat. Immunol. 11: 1080-1082.
17. Kägi, D., F. Vignaux, B. Ledermann, K. Bürki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265: 528-530. (Pubitemid 24264998)
18. Millard, P. J., M. P. Henkart, C. W. Reynolds, and P. A. Henkart. 1984. Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors. J. Immunol. 132: 3197-3204. (Pubitemid 14104293)
19. Lieberman, J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3: 361-370. (Pubitemid 37323196)
20. Hirst, C. E., M. S. Buzza, C. H. Bird, H. S. Warren, P. U. Cameron, M. Zhang, P. G. Ashton-Rickardt, and P. I. Bird. 2003. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J. Immunol. 170: 805-815. (Pubitemid 36070532)
21. Zhang, M., S. M. Park, Y. Wang, R. Shah, N. Liu, A. E. Murmann, C. R. Wang, M. E. Peter, and P. G. Ashton-Rickardt. 2006. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 24: 451-461.
22. Zhang, M., N. Liu, S. M. Park, Y. Wang, S. Byrne, A. E. Murmann, S. Bahr, M. E. Peter, S. T. Olson, A. Belaaouaj, and P. G. Ashton-Rickardt. 2007. Serine protease inhibitor 6-deficient mice have increased neutrophil immunity to Pseudomonas aeruginosa. J. Immunol. 179: 4390-4396.
23. Bladergroen, B. A., M. C. Strik, N. Bovenschen, O. Van Berkum, G. L. Scheffer, C. J. Meijer, C. E. Hack, and J. A. Kummer. 2001. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J. Immunol. 166: 3218-3225. (Pubitemid 33117320)
24. Abdullah, Z., T. Saric, H. Kashkar, N. Baschuk, B. Yazdanpanah, B. K. Fleischmann, J. Hescheler, M. Krönke, and O. Utermöhlen. 2007. Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. J. Immunol. 178: 3390-3399. (Pubitemid 46417603)
25. Sun, J., C. H. Bird, V. Sutton, L. McDonald, P. B. Coughlin, T. A. De Jong, J. A. Trapani, and P. I. Bird. 1996. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 271: 27802-27809. (Pubitemid 26367355)
26. Medema, J. P., J. De Jong, L. T. Peltenburg, E. M. Verdegaal, A. Gorter, S. A. Bres, K. L. Franken, M. Hahne, J. P. Albar, C. J. Melief, and R. Offringa. 2001. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl. Acad. Sci. USA 98: 11515-11520. (Pubitemid 32928760)
27. Abdelhaleem, M. 2007. Cytotoxic granule disruption is a late event in chemotherapy-induced apoptosis in natural killer YT cells. Exp. Mol. Pathol. 83: 112-114. (Pubitemid 46842961)
28. Pittenger, M. F., and D. M. Helfman. 1992. In vitro and in vivo characterization of four fibroblast tropomyosins produced in bacteria: TM-2, TM-3, TM-5a, and TM-5b are co-localized in interphase fibroblasts. J. Cell Biol. 118: 841-858.
29. Delaney, M., C. S. Cutler, R. L. Haspel, B. Y. Yeap, S. L. McAfee, B. R. Dey, E. Attar, G. Kao, E. P. Alyea, J. Koreth, et al. 2009. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion 49: 995-1002.
30. Wang, X. M., P. I. Terasaki, G. W. Rankin, Jr., D. Chia, H. P. Zhong, and S. Hardy. 1993. A new microcellular cytotoxicity test based on calcein AM release. Hum. Immunol. 37: 264-270. (Pubitemid 23343716)
31. Willoughby, C. A., H. G. Bull, M. Garcia-Calvo, J. Jiang, K. T. Chapman, and N. A. Thornberry. 2002. Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg. Med. Chem. Lett. 12: 2197-2200. (Pubitemid 34804398)
32. Jones, G. J., J. C. Wiseman, K. J. Marr, S. Wei, J. Y. Djeu, and C. H. Mody. 2009. In contrast to anti-tumor activity, YT cell and primary NK cell cytotoxicity for Cryptococcus neoformans bypasses LFA-1. Int. Immunol. 21: 423-432.
33. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285: 727-729.
34. Shirakawa, F., Y. Tanaka, S. Eto, H. Suzuki, J. Yodoi, and U. Yamashita. 1986. Effect of interleukin 1 on the expression of interleukin 2 receptor (Tac antigen) on human natural killer cells and natural killer-like cell line (YT cells). J. Immunol. 137: 551-556. (Pubitemid 16045082)
35. Hodgkinson, C. P., J. A. Gomez, M. Mirotsou, and V. J. Dzau. 2010. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum. Gene Ther. 21: 1513-1526.
36. Zhang, L. S., Q. F. Liu, K. Huang, Y. Zhang, Z. P. Fan, and S. L. Huang. 2009. [Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease]. Zhonghua Nei Ke Za Zhi 48: 542-546.
37. Abdi, R., P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh. 2008. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57: 1759-1767.
38. Wexler, S. A., C. Donaldson, P. Denning-Kendall, C. Rice, B. Bradley, and J. M. Hows. 2003. Adult bone marrow is a rich source of human mesenchymal "stem" cells but umbilical cord and mobilized adult blood are not. Br. J. Haematol. 121: 368-374. (Pubitemid 36560606)
39. Tyndall, A., and A. Uccelli. 2009. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant. 43: 821-828.
40. Tondreau, T., N. Meuleman, A. Delforge, M. Dejeneffe, R. Leroy, M. Massy, C. Mortier, D. Bron, and L. Lagneaux. 2005. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells 23: 1105-1112. (Pubitemid 41377726)
41. Lund, T. C., J. Tolar, and P. J. Orchard. 2008. Granulocyte colony-stimulating factor mobilized CFU-F can be found in the peripheral blood but have limited expansion potential. Haematologica 93: 908-912. (Pubitemid 351821728)
42. Zvaifler, N. J., L. Marinova-Mutafchieva, G. Adams, C. J. Edwards, J. Moss, J. A. Burger, and R. N. Maini. 2000. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2: 477-488. (Pubitemid 32223796)
43. Kim, J., J. W. Kang, J. H. Park, Y. Choi, K. S. Choi, K. D. Park, D. H. Baek, S. K. Seong, H. K. Min, and H. S. Kim. 2009. Biological characterization of long-term cultured human mesenchymal stem cells. Arch. Pharm. Res. 32: 117-126.
44. Morito, A., Y. Kida, K. Suzuki, K. Inoue, N. Kuroda, K. Gomi, T. Arai, and T. Sato. 2009. Effects of basic fibroblast growth factor on the development of the stem cell properties of human dental pulp cells. Arch. Histol. Cytol. 72: 51-64.
45. Bian, Z. Y., G. Li, Y. K. Gan, Y. Q. Hao, W. T. Xu, and T. T. Tang. 2009. Increased number of mesenchymal stem cell-like cells in peripheral blood of patients with bone sarcomas. Arch. Med. Res. 40: 163-168.
46. Horwitz, E. M., K. Le Blanc, M. Dominici, I. Mueller, I. Slaper-Cortenbach, F. C. Marini, R. J. Deans, D. S. Krause, A. Keating; International Society for Cellular Therapy. 2005. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395. (Pubitemid 41671625)
47. Prockop, D. J., I. Sekiya, and D. C. Colter. 2001. Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy 3: 393-396. (Pubitemid 34784633)
48. Zhao, S., R. Wehner, M. Bornhauser, R. Wassmuth, M. Bachmann, and M. Schmitz. 2010. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 19: 607-614.
49. Nauta, A. J., and W. E. Fibbe. 2007. Immunomodulatory properties of mesenchymal stromal cells. Blood 110: 3499-3506. (Pubitemid 350159613)
50. Najar, M., R. Rouas, G. Raicevic, H. I. Boufker, P. Lewalle, N. Meuleman, D. Bron, M. Toungouz, P. Martiat, and L. Lagneaux. 2009. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11: 570-583.
51. Kunz, M., and S. M. Ibrahim. 2009. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm. 2009: 979258.
52. Chamberlain, G., J. Fox, B. Ashton, and J. Middleton. 2007. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25: 2739-2749. (Pubitemid 350127858)
53. Le Blanc, K., H. Samuelsson, B. Gustafsson, M. Remberger, B. Sundberg, J. Arvidson, P. Ljungman, H. Lönnies, S. Nava, and O. Ringdén. 2007. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733-1738. (Pubitemid 47086763)
54. Le Blanc, K., C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén. 2003. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31: 890-896. (Pubitemid 37211373)
55. Klyushnenkova, E., J. D. Mosca, V. Zernetkina, M. K. Majumdar, K. J. Beggs, D. W. Simonetti, R. J. Deans, and K. R. McIntosh. 2005. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12: 47-57. (Pubitemid 40576763)
56. Le Blanc, K., and O. Ringdén. 2007. Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262: 509-525. (Pubitemid 47620502)
57. Bots, M., E. De Bruin, M. T. Rademaker-Koot, and J. P. Medema. 2007. Proteinase inhibitor-9 expression is induced by maturation in dendritic cells via p38 MAP kinase. Hum. Immunol. 68: 959-964.
58. Sotiropoulou, P. A., S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail. 2006. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24: 74-85.